Toronto-based AI-native biopharma founded in 2023 by former RBCx venture-capital director Anthony Mouchantaf and physician Alexander Mosa. Uses large language models and embedding techniques to mine publicly available data on late-stage drug candidates that failed their original trials, then buys or licenses the most commercially promising molecules from their original owners and advances them through new clinical studies. Operates late-stage programs spanning sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease.
1
Round
1
Industry
5
Tags
Sep 28, 2026
Latest raise
Funding activity · 1 round
Sep 28, 2026
$153M
Series C+
Led by OpenAI Startup Fund
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
